Is there a prostate‐specific antigen upper limit for radical prostatectomy?

Paolo Gontero(Fondazione Ricerca Molinette), Steven Joniau, G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Burkhard Kneitz(Universitätsklinikum Würzburg), Bruno Frea(Ospedale Maggiore), Martin Spahn(Universitätsklinikum Würzburg), Hendrik Van Poppel(Universitair Ziekenhuis Leuven), A Tizzani(University of Turin), Kathy Van Der Eeckt(KU Leuven), D. Frohneberg(Städtisches Klinikum Karlsruhe), Pia Bader(Städtisches Klinikum Karlsruhe), Chao‐Yu Hsu(National Chung Hsing University), Bertrand Tombal(Cliniques Universitaires Saint-Luc)
British Journal of Urology
March 10, 2011
10.1111/j.1464-410x.2011.10076.x
Cited by 25

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
|European Urology|2015|639